Filtered By:
Drug: Lipitor

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 875 results found since Jan 2013.

Association of Long-Term Atorvastatin with Escalated Stroke-Induced Neuroinflammation in Rats
AbstractStatins are widely used in high-risk patients to reduce the stroke incidence. However, little has been investigated about the impact of chronic pretreatment with statins on cerebral ischemic insult following defined arterial occlusion. To address this in experimental rats, in the present work, atorvastatin was orally dosed for 1  month to evaluate the outcomes of the subsequent occlusive stroke induced by middle cerebral artery occlusion (MCAO). Our data was suggestive of potential escalating impact of chronic atorvastatin (Atv; 10 mg/kg) on neurological function, but not infarct volume. According to our immunobl...
Source: Journal of Molecular Neuroscience - August 18, 2016 Category: Neuroscience Source Type: research

Effect of Prior Atorvastatin Treatment on the Frequency of Hospital Acquired Pneumonia and Evolution of Biomarkers in Patients with Acute Ischemic Stroke: A Multicenter Prospective Study.
Conclusions. Prior atorvastatin treatment in patients with ischemic stroke was associated with a lower concentration of IL-6 and TNF-α and improved the outcome of VAP. This clinical study has been registered with ChiCTR-ROC-17010633 in Chinese Clinical Trial Registry. PMID: 28357403 [PubMed - in process]
Source: Biomed Res - April 1, 2017 Category: Research Authors: Yu Y, Zhu C, Liu C, Gao Y Tags: Biomed Res Int Source Type: research

Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam
Conclusion: Atorvastatin and aspirin co-treatment with levetiracetam can reduce epilepsy in PSE patients and reduce the dosage of levetiracetam required for effective control of PSE.
Source: Medicine - December 11, 2020 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research

Effects of long-term regular oral aspirin combined with atorvastatin to prevent ischemic stroke on human gut microbiota
CONCLUSIONS: Our findings indicated that long-term regular oral aspirin and atorvastatin modulate the human gut microbiota. Taking these drugs may affect the preventive effect of ischemic stroke by changing the abundance of specific gut microbiota.PMID:37201625 | DOI:10.1016/j.ejphar.2023.175800
Source: European Journal of Pharmacology - May 18, 2023 Category: Drugs & Pharmacology Authors: Guangtang Chen Zili Wang Wenxue Song Yidong Liao Xudong Wang Chen Chen Jiang Ming Junshuan Cui Kaya Xu Source Type: research

Cerebral Infarction in a Case of Parry-Romberg Syndrome
Our objective is to report a rare coexistence of Parry-Romberg disease and ischemic stroke. Here, we report the case of a 34-year-old woman with Parry-Romberg syndrome who developed cerebral infarction. This patient developed sudden left-sided weakness and was admitted to our hospital. Magnetic resonance imaging revealed acute cerebral infarction in the posterior limb of the right internal capsule. The patient had been diagnosed with Parry-Romberg syndrome at the age of 12, and she had a history of migraine without aura. Transesophageal echocardiography revealed a patent foramen ovale, but no atrial septal aneurysm or deep...
Source: Journal of Stroke and Cerebrovascular Diseases - May 9, 2013 Category: Neurology Authors: Yuji Tomizawa, Ryota Tanaka, Kiyoshi Sekiguchi, Yutaka Oji, Yasutaka Tanaka, Kazuo Yamashiro, Nobutaka Hattori Tags: Case Reports Source Type: research

Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke
There are no studies that compared the effects of different intensities of statin treatment on the long-term outcome of patients with recent ischemic stroke. We aimed to evaluate these effects. Methods: We prospectively studied 436 consecutive patients who were discharged after acute ischemic stroke (39.2% males, age 78.6±6.7 years). Statin treatment was categorized in equipotent doses of atorvastatin. One year after discharge, the functional status was assessed with the modified Rankin scale (mRS).
Source: Atherosclerosis - September 2, 2015 Category: Cardiology Authors: Konstantinos Tziomalos, Vasilios Giampatzis, Stella D. Bouziana, Marianna Spanou, Stavroula Kostaki, Maria Papadopoulou, Stella-Maria Angelopoulou, Filitsa Konstantara, Christos Savopoulos, Apostolos I. Hatzitolios Source Type: research

Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease
Abstract After careful review of randomized cardiovascular outcomes trial data, the 2013 ACC/AHA cholesterol guideline focused on using the appropriate intensity of statin therapy to reduce atherosclerotic cardiovascular disease (ASCVD) risk and moved away from recommending specific low-density lipoprotein cholesterol (LDL-C) treatment targets. In patients who have had a stroke or other clinical ASCVD event, a high-intensity statin should be initiated up to age 75 years unless there are safety concerns, including a history of hemorrhagic stroke. A moderate-intensity statin is recommended if there are safety conc...
Source: Current Neurology and Neuroscience Reports - February 2, 2016 Category: Neuroscience Source Type: research

Gene Polymorphisms Affect the Effectiveness of Atorvastatin in Treating Ischemic Stroke Patients
Background/Aims: The aim of the present study is to investigate whether the single nucleotide polymorphism (SNP) in lipid metabolism related genes would affect the effectiveness of atorvastatin in both Han and Uighur populations. Methods: 200 ischemic stroke patients were treated with atorvastatin. The differences of blood lipid level and their ratios were measured. Six lipid related genes, HMGCR, APOA5, LPL, CETP, LDLR and PCSK9 were selected as candidate genes. And nine SNP loci in these six genes were genotyped by SNaPshot technique. Results: In all patients treated with atorvastatin, the SNP rs662799 significantly affe...
Source: Cellular Physiology and Biochemistry - July 14, 2016 Category: Cytology Source Type: research

Association between the   TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy.
This study aimed to determine the TIMD4-HAVCR1 variants, their haplotypes and gene-environment interactions on serum lipid levels, the risk of CHD and IS, and the lipid-lowering efficacy of atorvastatin in a southern Chinese Han population. Genotypes of 3 variants in 622 controls, 579 CHD and 546 IS patients were determined by the Snapshot technology. Atorvastatin calcium tablet (20 mg/d) was given in 724 hyperlipidemic patients for 8 weeks after genotyping. The rs12522248 genotypic and allelic frequencies were different between controls and patients, and were associated with the risk of CHD and IS. The rs1501908G-rs125222...
Source: Bioscience Reports - December 5, 2017 Category: Biomedical Science Authors: Zhang QH, Yin RX, Chen WX, Cao XL, Chen YM Tags: Biosci Rep Source Type: research

Polymorphisms in CYP450 Genes and the Therapeutic Effect of Atorvastatin on Ischemic Stroke: A Retrospective Cohort Study in Chinese Population.
Abstract PURPOSE: Ischemic stroke (IS) is one of the most common neurologic diseases and is the main cause of death and disability in the Chinese population. This retrospective cohort study was performed to elucidate the relationship between single nucleotide polymorphisms (SNPs) in cytochrome P450 genes and the therapeutic effect of atorvastatin. METHODS: A total of 192 cases of IS were enrolled in the study. All patients were treated with atorvastatin, and their lipid levels and proportions were measured. Six SNPs in 4 cytochrome P450 genes (CYP2C19, CYP2D6, CYP3A4, and CYP4F2) related to drug metabolism we...
Source: Clinical Therapeutics - February 27, 2018 Category: Drugs & Pharmacology Authors: Peng C, Ding Y, Yi X, Shen Y, Dong Z, Cao L, Li Q, Ren H, He L, Zhou D, Chen X Tags: Clin Ther Source Type: research

PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging
BMJ Open. 2022 Apr 29;12(4):e060068. doi: 10.1136/bmjopen-2021-060068.ABSTRACTINTRODUCTION: Dual antiplatelet therapy and high-intensity statins are the mainstay treatment in patients with acute stage, symptomatic intracranial atherosclerotic stenosis (ICAS). Alirocumab is a monoclonal antibody that can inhibit proprotein convertase subtilisin-kexin type 9 and effectively lower low-density lipoprotein cholesterol levels with less side effects than statins. We hypothesise that alirocumab treatment in addition to statin therapy could stabilise intracranial plaque and reduce arterial stenosis.METHODS AND ANALYSIS: In this pro...
Source: Atherosclerosis - April 29, 2022 Category: Cardiology Authors: Yen-Chu Huang Chia-Hao Chang Yuan-Hsiung Tsai Hsu-Huei Weng Leng-Chieh Lin Jiann-Der Lee Source Type: research

Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic stroke
(Neural Regeneration Research) A recent study by Lianqiu Min and colleagues from Liaoning Medical University observed the effects of atorvastatin treatment in 89 patients from northeastern China with acute ischemic stroke caused by intracranial large-artery atherosclerosis by measuring changes in the levels of markers of inflammation, thrombogenesis, and hyperlipidemia.
Source: EurekAlert! - Medicine and Health - September 10, 2013 Category: Global & Universal Source Type: news

Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke
Conclusions: Pre-treatment with PPARalpha agonist or atorvastatin show potential neuroprotective effects by inhibiting the PDI overexpression in conjunction with the preservation of other neuronal markers, several of which are associated with the regulation of protein homeostasis, signal transduction and maintenance of synaptic plasticity. This proteomic study therefore suggests that neuroprotective effect of PPARalpha agonists supposes the preservation of the expression of several proteins essential for the maintenance of protein homeostasis not necessarily directly linked to PPARalpha known-regulated targets.
Source: Proteome Science - May 6, 2014 Category: Bioinformatics Authors: Patrick GeléValérie VingtdeuxCamille PoteyHervé DrobecqAntoine GhestemPatricia MelnykLuc BuéeNicolas SergeantRégis Bordet Source Type: research